Category Finance

Letter Shows US Pressure On Global Fund For Compulsory Licensing, Generics

A 2011 letter from the top Republican on the United States Senate Finance Committee condemned efforts by the Global Fund to train public health officials on the use of flexibilities to the patent system contained in international trade rules. The letter, which also attacked the purchase of generic medicines over brand-name drugs, came just months before the US helped remove the head of the Global Fund, ultimately replacing him with an American official.

FAO: New GMOs Rising In Developing Countries; Public Sector Key

Contributions of participants at a recent e-conference organised by the Food and Agriculture Organization of the United Nations (FAO) on new genetically modified organisms show that a considerable number of new GMOs are likely to be released in developing countries in the next five years.

Mediator’s Report On EU Copyright Levies Recommends Major Changes

Copies made by end-users for private purposes in the context of a service previously licensed by copyright holders don't cause harm that should be subject to private copying levies on reproduction devices such as MP3 players, blank DVDs and photocopiers, a European Commission-appointed mediator said in recommendations published on 31 January. António Vitorino suggested major changes to Europe's copy levy system to align it with the digital world, but said at a press briefing that “there is still some way to go” to bring stakeholder positions together.

Potential Elements Of The WHO Global R&D Treaty: Tailoring Solutions For Disparate Contexts

Prof. Ryan Abbott analyzes the key components of the WHO proposal for a Global R&D Treaty and their potential impact on public health. The article proposes strategies to convert parties currently opposing the treaty, and argues that a stratified limited market-exclusivity regime has the capacity for a meaningful impact.

WHO Board Approves Resolution On Neglected Diseases; Sets Action On Substandard Medicines

The World Health Organization Executive Board today approved a modified resolution on neglected tropical diseases – after removing a reference to a working group on R&D for neglected diseases as “irrelevant”. The Board also discussed and took note of a report on poor quality medical products in the supply chain, and agreed to set another meeting on the issue before the May World Health Assembly, as well as set up a separate group on behaviours that lead to this problem.

Debate Erupts At WHO Over “Consensus” On Financing R&D For The Poor

World Health Organization members on Friday held a tense discussion over legal and political aspects of a consensus reached by a small number of member states in November on implementing a plan to address the global lack of research and development for neglected diseases predominantly afflicting poor populations. The discussion may continue today, with the linkage of an agenda item on neglected tropical diseases and the report of an expert working group offering numerous ideas for addressing the problem.

Official Offers Reflections On WHO Reform, Private Sector Role

In 2011, Margaret Chan, director general of the World Health Organization, launched a major reform of the United Nations organisation. This week, a presentation and discussions around the WHO reform by Gaudenz Silberschmidt, senior adviser in the WHO Office of the Director-General, highlighted the reason for this reform, its organisation and the possible impact the reform could have on the relationship between the pharmaceutical industry and the WHO.

Free Drugs Are “Crucial Part” Of Neglected Tropical Disease Fight

The World Health Organization reports that unprecedented progress has been made in addressing 17 parasitic diseases affecting the world’s poorest populations. The public health authority attributes the gains, in large part, to the contributions of global partners, including drug contributions made by research-based pharmaceutical giants.